Teduglutide: The GLP-2 Peptide Drug That Helps Damaged Guts Regrow and Absorb Again
Teduglutide, a GLP-2 analog, regenerates intestinal tissue in short bowel syndrome patients, reducing diarrhea by 700 g/day and decreasing dependence on IV nutrition in Phase III trials.
Quick Facts
What This Study Found
Teduglutide, a GLP-2 analog, promotes intestinal mucosal growth and restores absorptive function in patients with short bowel syndrome (SBS), reducing their dependence on intravenous parenteral nutrition (PN). In a Phase II study, teduglutide reduced diarrhea by approximately 700 g/day and fecal energy losses by about 0.8 MJ/day over 3 weeks. Two Phase III randomized placebo-controlled 24-week trials confirmed these results, showing significant improvements in intestinal fluid absorption.
The drug works by enhancing the structural and functional integrity of remaining intestine — essentially making the surviving gut more efficient at absorbing nutrients and fluid. This translated to measurable reductions in the volume and frequency of parenteral support needed, significantly improving patients' quality of life.
Key Numbers
~700 g/day diarrhea reduction · ~0.8 MJ/day fecal energy loss reduction · 24-week Phase III trials · 2 randomized placebo-controlled trials · up to 24 weeks safety data
How They Did This
Review covering teduglutide's mechanism of action, Phase II metabolic balance study results, and two Phase III randomized, placebo-controlled, 24-week clinical trials in patients with short bowel syndrome and intestinal failure.
Why This Research Matters
Short bowel syndrome patients who can't absorb enough nutrients depend on IV nutrition (parenteral support) delivered through a central line — a lifesaving but burdensome treatment that carries risks of bloodstream infections, blood clots, and liver disease. Teduglutide is the first drug to address the root problem by regenerating intestinal tissue and improving absorption, potentially freeing patients from some or all of their IV nutrition dependence.
The Bigger Picture
GLP-1 gets all the headlines for weight loss, but its sibling GLP-2 has its own revolutionary application. Teduglutide (brand name Gattex/Revestive) was subsequently FDA-approved and represents the first drug that actually regrows intestinal tissue. For the short bowel syndrome community — roughly 10,000-20,000 patients in the US — it changed the treatment paradigm from managing a damaged gut to regenerating it. The success of teduglutide also validates GLP-2 as a therapeutic target for other intestinal conditions.
What This Study Doesn't Tell Us
Studies covered up to 24 weeks in duration — long-term safety and efficacy data (years of treatment) were not yet available at time of publication. The review was published before FDA approval, so post-marketing safety data is not included. Teduglutide promotes mucosal growth, raising theoretical concerns about intestinal polyps that require ongoing monitoring.
Questions This Raises
- ?Can teduglutide eventually allow some short bowel syndrome patients to completely stop parenteral nutrition?
- ?What is the long-term safety profile regarding intestinal polyp formation with chronic mucosal growth stimulation?
- ?Could GLP-2 analogs benefit other intestinal conditions like Crohn's disease or radiation enteritis?
Trust & Context
- Key Stat:
- ~700 g/day Teduglutide reduced diarrhea output by approximately 700 grams per day in a Phase II study — a clinically meaningful improvement for patients who may produce liters of liquid stool daily
- Evidence Grade:
- This review covers Phase II and Phase III randomized placebo-controlled trial data published in a peer-reviewed gastroenterology journal. The evidence is strong — teduglutide was subsequently FDA-approved based on these and additional studies.
- Study Age:
- Published in 2012 in Therapeutic Advances in Gastroenterology, before teduglutide's FDA approval (December 2012). The trial data described here directly supported regulatory approval. Years of post-marketing experience have since confirmed the safety and efficacy profile.
- Original Title:
- Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome.
- Published In:
- Therapeutic advances in gastroenterology, 5(3), 159-71 (2012)
- Authors:
- Jeppesen, Palle Bekker
- Database ID:
- RPEP-01971
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is short bowel syndrome and why is it so serious?
Short bowel syndrome occurs when large portions of the small intestine are removed or damaged, leaving too little gut to absorb adequate nutrition from food. Patients often depend on IV nutrition (parenteral support) delivered through a permanent central line — which carries risks of serious infections, blood clots, and liver damage.
How does teduglutide help the gut regrow?
Teduglutide mimics GLP-2, a natural gut hormone that tells intestinal cells to grow and multiply. By stimulating mucosal growth, it increases the absorptive surface area of the remaining intestine, helping it absorb more fluid and nutrients. This can reduce or eliminate the need for IV nutrition in some patients.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01971APA
Jeppesen, Palle Bekker. (2012). Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome.. Therapeutic advances in gastroenterology, 5(3), 159-71. https://doi.org/10.1177/1756283X11436318
MLA
Jeppesen, Palle Bekker. "Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome.." Therapeutic advances in gastroenterology, 2012. https://doi.org/10.1177/1756283X11436318
RethinkPeptides
RethinkPeptides Research Database. "Teduglutide, a novel glucagon-like peptide 2 analog, in the ..." RPEP-01971. Retrieved from https://rethinkpeptides.com/research/jeppesen-2012-teduglutide-a-novel-glucagonlike
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.